Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Nab-paclitaxel +/- Pitavastatin in Maintenance Treatment of Unresectable Pancreatic Adenocarcinoma
NCT07549958Phase 1Recruiting
- Sponsor
- University of California, Irvine
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pitavastatin in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by University of California, Irvine. Primary endpoint: Recommended Phase II Dose at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
pitavastatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07549958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549958.